Can I read The Role of 2‐Chlorodeoxyadenosine in the Treatment of Patients with Refractory Angioimmunoblastic Lymphadenopathy with Dysproteinemia on EtoBox?

The Role of 2‐Chlorodeoxyadenosine in the Treatment of Patients with Refractory Angioimmunoblastic Lymphadenopathy with Dysproteinemia by Sabah Sallah; Robert Wehbie; Pamela Lepera; Waddah Sallah; William Bobzien is a Medicine article available to read on EtoBox.

What is The Role of 2‐Chlorodeoxyadenosine in the Treatment of Patients with Refractory Angioimmunoblastic Lymphadenopathy with Dysproteinemia about?

Treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) often constitutes a challenge for the clinical haematologist. Single‐ agent and combination chemotherapy have failed to increase the response rate or survival of patients with AILD. A total of seven patients with refractory or relapsed AILD were treated with 2‐chlorodeoxyadenosine (2‐CdA) for variable number of cycles. The overall response rate was 57% with two patients (28.5%) achieving complete and sustained response. 2‐Chlorodeoxyadenosine appears to be an active agent for patients with previously treated AILD. Phase II studies evaluating the efficacy of this agent as front‐line treatment for AILD are justified, especially in the absence of any effective therapy for this disorder.

Who reads The Role of 2‐Chlorodeoxyadenosine in the Treatment of Patients with Refractory Angioimmunoblastic Lymphadenopathy with Dysproteinemia?

Author

Sabah Sallah; Robert Wehbie; Pamela Lepera; Waddah Sallah; William Bobzien

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0007-1048)

Published

1999

Language

EN

Field

Medicine (Health Sciences)